News from Oblita and TT4CL partners
Follow our latest newsDevelopment of a new leishmaniasis drug wins EU funding
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and their social and economic impacts. Funding from Horizon 2020,...